CA2292835A1 - Ntn-2 member of tnf ligand family - Google Patents

Ntn-2 member of tnf ligand family Download PDF

Info

Publication number
CA2292835A1
CA2292835A1 CA002292835A CA2292835A CA2292835A1 CA 2292835 A1 CA2292835 A1 CA 2292835A1 CA 002292835 A CA002292835 A CA 002292835A CA 2292835 A CA2292835 A CA 2292835A CA 2292835 A1 CA2292835 A1 CA 2292835A1
Authority
CA
Canada
Prior art keywords
human ntn
human
ntn
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002292835A
Other languages
English (en)
French (fr)
Inventor
Piotr Masiakowski
David Valenzuela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2292835A1 publication Critical patent/CA2292835A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002292835A 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family Abandoned CA2292835A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4877697P 1997-06-06 1997-06-06
US60/048,776 1997-06-06
US6638797P 1997-11-21 1997-11-21
US60/066,387 1997-11-21
PCT/US1998/011294 WO1998055621A1 (en) 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family

Publications (1)

Publication Number Publication Date
CA2292835A1 true CA2292835A1 (en) 1998-12-10

Family

ID=26726521

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002292835A Abandoned CA2292835A1 (en) 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family
CA002292899A Abandoned CA2292899A1 (en) 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002292899A Abandoned CA2292899A1 (en) 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family

Country Status (6)

Country Link
EP (1) EP0991759A1 (ja)
JP (1) JP2002517977A (ja)
AU (1) AU7608898A (ja)
CA (2) CA2292835A1 (ja)
IL (1) IL133316A0 (ja)
WO (1) WO1998055621A1 (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999026463A2 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
WO1999033980A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
AU1467000A (en) * 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
BR0007423A (pt) * 1999-01-07 2002-01-22 Zymogenetics Inc Métodos para inibir a atividade de ztnf4 em um mamìfero e o acoplamento de receptor-ligando br43x2, taci ou bcma e para produzir um polipeptìdeo, molécula de polinucleotìdeo isolada, vetor de expressão, célula cultivada, e, polipeptìdeo isolado
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
HUP0105283A3 (en) 1999-01-25 2004-08-30 Biogen Idec Ma Inc Cambridge Baff, inhibitors thereof and their use in the modulation of b-cell response
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
WO2000047740A2 (en) * 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
EE05673B1 (et) 1999-08-17 2013-08-15 Biogen, Inc. BAFF-retseptor (BCMA), immunoregulatoorne agens
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001087979A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
KR101287395B1 (ko) 2000-06-16 2014-11-04 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP2292655B1 (en) 2001-05-11 2012-03-14 Amgen SF, LLC Peptides and related molecules that bind to tall-1
PT1436003E (pt) 2001-05-24 2010-03-12 Zymogenetics Inc Proteínas de fusão imunoglobulina taci
CA2520097C (en) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Truncated baff receptors
US20050255560A1 (en) * 2003-11-21 2005-11-17 Zeren Gao Ztnf11, a tumor necrosis factor
CA2583900A1 (en) * 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
KR20080056714A (ko) 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
CN106367714A (zh) 2015-07-24 2017-02-01 先健科技(深圳)有限公司 铁基可吸收植入医疗器械与预制管及其制备方法
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT939804E (pt) * 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents

Also Published As

Publication number Publication date
CA2292899A1 (en) 1998-12-10
JP2002517977A (ja) 2002-06-18
EP0991759A1 (en) 2000-04-12
WO1998055621A1 (en) 1998-12-10
IL133316A0 (en) 2001-04-30
AU7608898A (en) 1998-12-21

Similar Documents

Publication Publication Date Title
AU743490B2 (en) NTN-2 member of TNF ligand family
CA2292835A1 (en) Ntn-2 member of tnf ligand family
US6475987B1 (en) Tall-1 receptor homologues
BG65519B1 (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
KR100620334B1 (ko) 헤르페스 심플렉스 바이러스 유입 매개체에 대한 리간드및 사용 방법
AU9230398A (en) Cysteine rich receptors-train
EP1019502A2 (en) Human orphan receptor ntr-1
JPH11225774A (ja) 免疫グロブリン遺伝子スーパーファミリーのメンバー、ｐｉｇｒ−１
US20020160451A1 (en) Novel orphan receptors
AU748167B2 (en) Novel nucleic acid and polypeptide
WO1997042321A9 (en) Osteoclast transporter protein
WO1997042321A1 (en) Osteoclast transporter protein
WO1999026980A1 (en) Methods and reagents for the utilization of sap family member proteins, novel signal transduction regulators
AU753400C (en) Orphan receptors
US6207413B1 (en) Nucleic acids encoding novel orphan cytokine receptors
JPH11215989A (ja) 免疫グロブリン遺伝子スーパーファミリーのメンバー、ｐｉｇｒ−２
JPH1072495A (ja) 免疫関連因子

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20030603